Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 14/20 | 0.42 |
| ▸ | CTSL | P07711 | 6/20 | 0.35 |
| ▸ | CTSS | P25774 | 6/20 | 0.35 |
| ▸ | CTSB | P07858 | 2/20 | 0.35 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4041110 | 0.94 | CTSK (0.42) | CTSKCTSLCTSSCTSBHTRA1 | |
| SCHEMBL4041956 | 0.94 | CTSK (0.46) | CTSKCTSLCTSSCTSBMEN1 | |
| SCHEMBL4046677 | 0.92 | CTSK (0.34) | CTSKCTSSMMP1MMP13 | |
| SCHEMBL4039264 | 0.91 | CTSK (0.40) | CTSKCTSLCTSSCTSBHTRA1 | |
| SCHEMBL4044566 | 0.90 | CTSK (0.42) | CTSKCTSLCTSSCTSBMEN1 | |
| SCHEMBL4050222 | 0.89 | CTSK (0.43) | CTSKCTSLCTSSCTSBMEN1 | |
| SCHEMBL4041636 | 0.89 | CTSK (0.47) | CTSKCTSSCTSBMEN1KMT2A | |
| SCHEMBL4037989 | 0.88 | CTSK (0.42) | CTSKCTSLCTSSCTSBKMT2A | |
| SCHEMBL4045808 | 0.87 | CTSK (0.54) | CTSKCTSLCTSSCTSBHTRA1 | |
| SCHEMBL4049257 | 0.87 | CTSK (0.41) | CTSKCTSLCTSSCTSBHTRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | claimed |